Management of adverse events associated with idelalisib treatment: expert panel opinion

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing informati...

Descripción completa

Detalles Bibliográficos
Autores principales: Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732460/
https://www.ncbi.nlm.nih.gov/pubmed/25726955
http://dx.doi.org/10.3109/10428194.2015.1022770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732460/
https://www.ncbi.nlm.nih.gov/pubmed/25726955
http://dx.doi.org/10.3109/10428194.2015.1022770

Ejemplares similares